A Nigerian manufacturer obtains a sublicence to develop and manufacture a patented antiviral; African nexus is party domicile and manufacturing location.
| Record ID | TX-AFR-2026-0022 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Sublicence, Patent licence, Technology transfer, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2026-09-24 |
| Sector | Life sciences · Pharmaceuticals – antivirals |
| African markets | Nigeria |
| Licensed territory | 129 low- and middle-income countries, subject to regulatory authorisation. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 3 source(s) |
| Last verified | 2026-10-25 |
Parties
- Medicines Patent Pool Foundation (Switzerland): sublicensor
- Fidson Healthcare Plc (Nigeria): sublicensee, manufacturer
Key terms
- Interest: sublicence; Exclusivity: not exclusive; Territorial scope: 129 low- and middle-income countries
Sources
- MPP signs sublicence agreements with generic manufacturers to expand access to influenza treatment and strengthen pandemic preparedness, Medicines Patent Pool, 2026-09-25
- Fidson Selected as Regional Sublicensee to Expand Access to Influenza Treatment and Strengthen Pandemic Preparedness, Fidson Healthcare, 2026-09-29
- Fidson wins Roche-backed licence to make generic influenza drug for 129 countries, BusinessDay (Nigeria), 2026-10-03
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.
